Breast cancer remains one of the most commonly diagnosed cancers worldwide. In 2022 alone, an estimated 2.3 million women were newly diagnosed, and approximately 670,000 deaths were linked to the disease globally.

While treatment options for breast cancer have expanded significantly, deciding how aggressively to treat each patient remains a major challenge. Some people benefit from intensive therapies such as chemotherapy, while others may safely avoid them.

A newly cleared artificial intelligence-based tool may help doctors make those decisions with greater precision.

The U.S. Food and Drug Administration recently cleared ArteraAI Breast, a digital pathology-based risk assessment system designed for patients with early-stage hormone receptor-positive (HR+), HER2-negative invasive breast cancer.

How the AI Tool Works

The system analyzes digital images created from pathology slides after a tumor has been surgically removed.

Using artificial intelligence, the platform combines:

  • digitized tissue images
  • clinical information
  • patterns learned from thousands of prior breast cancer cases

The model was trained using data from more than 8,500 breast cancer patients enrolled in clinical trials.

Its goal is to estimate the likelihood that a patient’s cancer could later spread to distant parts of the body — a process known as metastasis.

Based on the results, patients are classified into lower-risk or higher-risk categories.

Why Risk Prediction Matters

Breast cancer treatment is highly individualized. Patients with similar diagnoses may still face very different risks of recurrence.

For people with lower-risk disease, avoiding unnecessary chemotherapy can be important. Chemotherapy may cause both short-term and long-term side effects, including:

  • fatigue
  • nausea
  • nerve damage (neuropathy)
  • infection risk
  • fertility complications

At the same time, undertreatment can allow cancer to return or spread.

The AI system is intended to help oncologists better determine which patients are most likely to benefit from additional treatment intensity.

Existing Testing Options

Doctors already use genomic tests such as Oncotype DX to estimate recurrence risk in certain breast cancer patients. These tests analyze tumor biology and can help guide decisions about adding chemotherapy to hormone therapy.

However, these tests may involve:

  • additional costs
  • processing delays
  • limited availability in some settings

Results can also take several weeks.

The newly cleared AI-based system differs because it uses pathology images and clinical data that are often already available shortly after surgery. Researchers say this could potentially shorten waiting times and reduce barriers to risk assessment.

Potential Benefits for Patients

Specialists say the technology may be especially useful for patients whose treatment decisions are less clear-cut.

This includes some postmenopausal women and patients with early-stage tumors where the expected benefit of chemotherapy is uncertain.

In these “gray-zone” cases, additional risk information may help patients and clinicians make more confident decisions.

Reducing unnecessary chemotherapy could also lessen physical, emotional, and financial burdens for lower-risk patients.

Questions Still Remain

Although experts describe the FDA clearance as an important milestone, many clinicians say further evidence will be necessary before widespread adoption.

Researchers and oncologists want to see:

  • long-term patient outcome data
  • direct comparisons with existing genomic tests
  • evidence across diverse patient populations
  • real-world performance in clinical practice

Some specialists also emphasize the need for transparency regarding how the AI model generates its predictions.

Understanding which tumor features influence the system’s recommendations may help physicians evaluate its reliability and integrate it into patient care more confidently.

The Growing Role of AI in Cancer Care

Artificial intelligence is increasingly being explored across oncology, including in imaging, pathology, treatment planning, and drug development.

Supporters believe AI tools may eventually help physicians identify patterns too subtle for the human eye alone, potentially improving accuracy and personalization in cancer treatment.

At the same time, experts caution that AI systems are intended to support — not replace — clinical judgment.

For now, specialists say tools like ArteraAI Breast represent an early but significant step toward more individualized breast cancer care, with the possibility of helping patients receive treatment that better matches their level of risk.